Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Galapagos NV | Filgotinib - (SELECTION) | Ulcerative colitis | Phase 3 | Trial Completed | Oral | Gastroenterology |
| Galapagos NV | GLPG3667 - (GALARISSO) | Dermatomyositis | Phase 2 | Enrollment Initiation | Oral | Immunology |
| Galapagos NV | Filgotinib - (DIVERSITY) | Crohn’s disease | Phase 3 | Oral | Gastroenterology | |
| Galapagos NV | Jyseleca (filgotinib) - (SELECTION LTE) | Ulcerative Colitis (UC) | Phase 2/3 | Trial Discontinued | Oral | Gastroenterology |
| Galapagos NV | GLPG3667 - (GALARISSO) | Duchenne Muscular (DM) | Phase 2 | Data Released | Oral | Genetic Disorder |
| Galapagos NV | GLPG3970 (LADYBUG) | Rheumatoid Arthritis | Phase 2a | Oral | Immunology: Anti-TNF | |
| Galapagos NV | GLPG3667 - (GALACELA) | Systemic lupus erythematosus (SLE) | Phase 2 | Ongoing | oral | Immunology |
| Galapagos NV | Filgotinib | Non-infectious uveitis | Phase 2 | Oral | Opthalmic |
